NasdaqGS - Nasdaq Real Time Price USD

Syndax Pharmaceuticals, Inc. (SNDX)

21.15 +0.19 (+0.91%)
As of 1:55 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael A. Metzger M.B.A. CEO & Director 1.1M 126.68k 1971
Dr. Neil Gallagher M.D., Ph.D. President, Head of Research & Development 720.46k -- 1964
Mr. Keith Alan Goldan CPA CFO, Treasurer & Chief Accounting Officer 674.65k -- 1971
Mr. Luke J. Albrecht Senior VP, General Counsel & Secretary 631.36k 387.36k 1979
Dr. Catherine Madigan M.D. Chief Medical Officer 655.84k -- 1972
Dr. Peter Ordentlich B.Sc., Ph.D. Co-Founder & Chief Scientific Officer -- -- 1969
Dr. Richard A. Heyman Ph.D. Co-Founder -- -- 1957
Dr. Ronald M. Evans Ph.D. Co-Founder, Advisor and Chair of Scientific Advisory Board -- -- 1949
Dr. Michael Downes Ph.D. Co-Founder -- -- --
Sharon Klahre Vice President of Investor Relations & Communications -- -- --

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400 https://www.syndax.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
184

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Syndax Pharmaceuticals, Inc. Earnings Call

Related Tickers

MRUS Merus N.V.
41.41
+2.37%
 
KURA Kura Oncology, Inc.
18.97
+4.26%
 
CRNX Crinetics Pharmaceuticals, Inc.
44.37
+2.13%
 
XENE Xenon Pharmaceuticals Inc.
41.19
+2.95%
 
EWTX Edgewise Therapeutics, Inc.
15.76
+4.51%
 
SWTX SpringWorks Therapeutics, Inc.
45.21
+5.41%
 
XNCR Xencor, Inc.
18.60
+2.11%
 
MLTX MoonLake Immunotherapeutics
42.86
+4.49%
 
FDMT 4D Molecular Therapeutics, Inc.
25.31
-4.09%
 
RCUS Arcus Biosciences, Inc.
15.03
+2.38%